Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2006-03-21
2006-03-21
Yu, Misook (Department: 1642)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C424S184100
Reexamination Certificate
active
07014848
ABSTRACT:
The present invention provides methods for inducing an antigen-specific immune response by administering allogeneic antigen-presenting cells to a subject. In another aspect, an effective amount of autologous antigen-presenting cells are co-administered to a subject.
REFERENCES:
patent: 5633234 (1997-05-01), August et al.
patent: 5728388 (1998-03-01), Terman
patent: 5856180 (1999-01-01), Granucci
patent: WO94/28113 (1994-12-01), None
patent: WO 97/10002 (1997-03-01), None
patent: WO 97/19169 (1997-05-01), None
Riott et al (1996, Immunology, 19.8-9).
Larsen, C.P. et al., “Migration and maturation of Langerhans cells in skin transplants and explants”, Journal of Experimental Medicine, Nov. 1990, 172:1483-1493.
Maraskovsky, E. et al., “Dramatic Increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dedritic cell subpopulations identifed”, Journal of Experimental Medicine, Nov. 1996, 184(5):1953-1962.
Siena, S. et al., “Massive ex vivo generation of functional dendritic cells from mobilized CD34+ blood progenitors for anticancer therapy”, Experimental Hematology, 1995, 23:1463-1471.
Wan, Y. et al., “Dendritic cells transduced with an adenoviral vector encoding a model tumor-associated antigen for tumor vaccination”, Human Gene Therapy, Jul. 1997, 8:1355-1363.
Specht et al., “Dendritic Cells Retrovirally Transduced with a Model Antigen Gene Therapeutically Effective Against Established Pulmonary Metastases”, The Journal of Experimental Medicine, Oct. 1997, 186(8):1213-1221.
Reeves et al., “Retroviral Transduction of Human Dendritic Cells with a Tumor-Associated Antigen Gene”, Cancer Research, Dec. 1996, 56:5672-5677.
Young et al., “Dendritic Cells as Adjuvants for Class I Major Histocompatibility Complex-restricted Antitumor Immunity”, Journal of Experimental Medicine, Jan. 1996, 183:7-11.
de Zoeten, E.F. et al., “Resistance to Melanoma in Mice Immunized with Semiallogeneic Fibroblasts Transfected with DNA from Mouse Melanoma Cells”, The Journal of Immunology, Mar. 1998, 160:2915-2922.
Cavallo, F. et al., “Protective and curative potential of vaccination with interleukin-2-gene-transfected cells from a spontaneous mouse mammary adenocarcinoma”, Cancer Research, Nov. 1993, 53:5067-5070.
Russell, S.J. et al., “Decreased tumorigenicity of a transplantable rat sarcoma following transfer and expression of an IL-2-cDNA”, International Journal of Cancer, 1991, 47:244-251.
Chakravarty, P.K. et al., “Tumorigenicity of interleukin-2 (IL-2)-cDNA-transfected L1210 lymphoma and its in vivo variants is modulated by changes in IL-2 expression: potential therapeutic implications”, Cancer Immunology Immunotherapy, 1992, 35:347-354.
Hui, K.M., et al., “Tumor Rejection Mediated by Transfection with Allongeneic Class I Histocompatibility Gene”, The Journal of Immunology, Dec. 1989, 143(11):3835-3843.
Ostrand-Rosenberg, S. et al., “Rejection of Mouse Sarcoma Cells After Transfection of MHC Class II Genes”, The Journal of Immunology, May 1990, 144(10):4068-4071.
Nabel, G.J. et al., “Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes”, Proc. National Academy of Science, Dec. 1996, 93:15388-15393.
Pershwa, M.V. et al., “Generation of Primary Peptide-Specific CD8+ Cytotoxic T-Lymphocytes In Vitro Using Allogeneic Dendritic Cells”, Cell Transplantation, 1998, 7(1):1-9.
Dietz and Vuk-Pavlovic, “High Efficiency Adenovirus-Mediated Gene Transfer to Human Dendritic Cells”, Blood, Jan. 1998, 91(2):392-398.
Doll, R. et al., “Adenoviral Infection of Human Dendritic Cells for use as Antitumor Vaccines”, Cancer Gene Therapy, Nov. 1997, 4(6):S51-S52.
Kaplan Johanne
Scaria Abraham
Genzyme Corporation
Yu Misook
LandOfFree
Enhanced anti-tumor immunity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Enhanced anti-tumor immunity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Enhanced anti-tumor immunity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3557415